open access

Vol 8, No 2 (2005)
Images in Medicine
Submitted: 2012-01-23
Published online: 2005-06-23
Get Citation

99mTc-EDDA/HYNIC-octreotate - a new radiotracer for detection and staging of NET. A case of metastatic duodenal carcinoid

Alicja Hubalewska-Dydejczyk, Piotr Szybiński, Katarzyna Fröss-Baron, Renata Mikolajczak, Bohdan Huszno, Anna Sowa-Staszczak
Nucl. Med. Rev 2005;8(2):155-156.

open access

Vol 8, No 2 (2005)
Interesting image
Submitted: 2012-01-23
Published online: 2005-06-23

Abstract

Somatostatin receptor scintigraphy (SRS) has become a routine imaging method for the diagnostics of neuroendocrine tumours (NET). 99mTc-EDDA/HYNIC-octreotate (Polatom, Poland) is a new radiotracer with high affinity for SSTR2 and similar physiological biodistribution to 111In-Octreoscan.
We present a case of a 47-year-old man with disseminated duodenal carcinoid. The patient had been operated due to the tumour mass detected in pancreatic head area. Histopathology revealed carcinoid of the duodenal wall with local lymph node and liver metastases. The patient was qualified for chemotherapy stopped due to severe leucopenia. 99mTc EDDA/HYNIC-octreotate scintigraphy was performed for staging and to determine SSTR status of the tumour before planned 90Y-DOTATATE therapy. The multiple metastatic lesions were detected all over the body. The high quality images with high target/non target ratio were obtained. 99mTc-MDP scintigraphy confirmed multiple bone metastases. On the basis of SRS result the patient was qualified for 90Y-DOTA-TATE therapy. In conclusion, 99mTc EDDA/HYNIC-octreotate can be regarded as a promising tracer for staging and to determine SSTR status of NET.

Abstract

Somatostatin receptor scintigraphy (SRS) has become a routine imaging method for the diagnostics of neuroendocrine tumours (NET). 99mTc-EDDA/HYNIC-octreotate (Polatom, Poland) is a new radiotracer with high affinity for SSTR2 and similar physiological biodistribution to 111In-Octreoscan.
We present a case of a 47-year-old man with disseminated duodenal carcinoid. The patient had been operated due to the tumour mass detected in pancreatic head area. Histopathology revealed carcinoid of the duodenal wall with local lymph node and liver metastases. The patient was qualified for chemotherapy stopped due to severe leucopenia. 99mTc EDDA/HYNIC-octreotate scintigraphy was performed for staging and to determine SSTR status of the tumour before planned 90Y-DOTATATE therapy. The multiple metastatic lesions were detected all over the body. The high quality images with high target/non target ratio were obtained. 99mTc-MDP scintigraphy confirmed multiple bone metastases. On the basis of SRS result the patient was qualified for 90Y-DOTA-TATE therapy. In conclusion, 99mTc EDDA/HYNIC-octreotate can be regarded as a promising tracer for staging and to determine SSTR status of NET.
Get Citation

Keywords

99m 99mTc-Tc-EDDA/HYNIC-octreotate; SRS; duodenal carcinoid

About this article
Title

99mTc-EDDA/HYNIC-octreotate - a new radiotracer for detection and staging of NET. A case of metastatic duodenal carcinoid

Journal

Nuclear Medicine Review

Issue

Vol 8, No 2 (2005)

Article type

Images in Medicine

Pages

155-156

Published online

2005-06-23

Page views

2128

Article views/downloads

1365

Bibliographic record

Nucl. Med. Rev 2005;8(2):155-156.

Keywords

99m 99mTc-Tc-EDDA/HYNIC-octreotate
SRS
duodenal carcinoid

Authors

Alicja Hubalewska-Dydejczyk
Piotr Szybiński
Katarzyna Fröss-Baron
Renata Mikolajczak
Bohdan Huszno
Anna Sowa-Staszczak

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl